Evidence map›Paper›PMID 22283430›Full record

ArticleJournal of medicinal chemistry2012

Substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and analogues: synthesis, cytotoxic activity, and study of the mechanism of action.

Aldo Andreani, Massimiliano Granaiola, Alessandra Locatelli, Rita Morigi, Mirella Rambaldi, Lucilla Varoli, Natalia Calonghi, Concettina Cappadone, Giovanna Farruggia, Claudio Stefanelli and 4 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Imidazo[2,1-ACS omega · 2019
    Article
  7. Synthesis of 3-(Imidazo[2,1-Molecules (Basel, Switzerland) · 2019
    Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Aldo AndreaniDipartimento di Scienze Farmaceutiche, Università di Bologna, Via Belmeloro 6, 40126 Bologna, Italy. aldo.andreani@unibo.it
Massimiliano Granaiola
Alessandra Locatelli
Rita Morigi
Mirella Rambaldi
Lucilla Varoli
Natalia Calonghi
Concettina Cappadone
Giovanna Farruggia
Claudio Stefanelli
Lanfranco Masotti
Tam L Nguyen
Ernest Hamel
Robert H Shoemaker

Funding

Intramural NIH HHS Z99 CA999999NCI NIH HHS N01 CO012400NCI NIH HHS N01-CO-12400NCI NIH HHS Y99 CA999999
6 · The paper itself

Abstract

The synthesis of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and analogues is reported. Their cytotoxic activity was evaluated according to protocols available at the National Cancer Institute (NCI), Bethesda, MD. The action of selected compounds was examined for potential inhibition of tubulin assembly in comparison with the potent colchicine site agent combretastatin A-4. The most potent compounds also strongly and selectively inhibited the phosphorylation of the oncoprotein kinase Akt in cancer cells. The effect of the most interesting compounds was examined on the growth of HT-29 colon cancer cells. These compounds caused the cells to arrest in the G2/M phase of the cell cycle, as would be expected for inhibitors of tubulin assembly.

Indexed as

Antineoplastic AgentsApoptosisCell DivisionCell Line, TumorCell ProliferationColchicineDrug Screening Assays, AntitumorEnzyme ActivationG2 PhaseHumansImidazolesIndolesMitogen-Activated Protein KinasesModels, MolecularPhosphorylationProtein BindingAntineoplastic AgentsColchicineImidazolesIndolesMitogen-Activated Protein KinasesProto-Oncogene Proteins c-aktThiazolesTubulinTubulin Modulators

Identifiers

PMID22283430
PMCPMC3297693

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.